Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 6
Submit an article Journal homepage
583
Views
9
CrossRef citations to date
0
Altmetric
Review

Investigational Janus kinase inhibitors in development for myelofibrosis

Prithviraj BoseDepartment of Leukemia, University of TX MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
,
Abdallah Abou ZahrDepartment of Leukemia, University of TX MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Srdan VerstovsekDepartment of Leukemia, University of TX MD Anderson Cancer Center, Houston, TX, USAView further author information
Pages 723-734 | Received 27 Feb 2017, Accepted 24 Apr 2017, Published online: 08 May 2017

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Prithviraj Bose. (2019) Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opinion on Orphan Drugs 7:10, pages 415-425.
Read now

Articles from other publishers (8)

T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge & D. J. Touw. (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clinical Pharmacokinetics 62:4, pages 559-571.
Crossref
Bilal Rah, Rafiq A Rather, Gh Rasool Bhat, Abdul Basit Baba, Ifra Mushtaq, Muzamil Farooq, Tahira Yousuf, Sadaf B Dar, Sabra Parveen, Rukhsana Hassan, Fozia Mohammad, Iqbal Qassim, Abida Bhat, Shazia Ali, Mahrukh Hamid Zargar & Dil Afroze. (2022) JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Frontiers in Pharmacology 13.
Crossref
Uddalak Bharadwaj, Moses M. Kasembeli, Prema Robinson & David J. Tweardy. (2020) Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacological Reviews 72:2, pages 486-526.
Crossref
Prithviraj Bose, Mansour Alfayez & Srdan Verstovsek. (2019) New Concepts of Treatment for Patients with Myelofibrosis. Current Treatment Options in Oncology 20:1.
Crossref
John Mascarenhas & Ronald Hoffman. (2018) Don't judge a JAK2 inhibitor by spleen response alone. The Lancet Haematology 5:2, pages e56-e57.
Crossref
Prithviraj Bose, Jason Gotlib, Claire N. Harrison & Srdan Verstovsek. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma Myeloma and Leukemia 18:1, pages 1-12.
Crossref
Marissa J. Schafer, Andrew J. Haak, Daniel J. Tschumperlin & Nathan K. LeBrasseur. (2018) Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations. Current Rheumatology Reports 20:1.
Crossref
Prithviraj Bose & Srdan Verstovsek. (2017) JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood 130:2, pages 115-125.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.